AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16240937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ; 10 mg/d) for 14 days
Number of subjects: 30
Study 16240937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with standard dose of systemic heparin
Number of subjects: 60
Study 12167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with high dose of systemic heparin
Number of subjects: 60
Study 12167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with low dose of systemic heparin
Number of subjects: 60
Study 12167793 — intervention group
Group type: COMPARATOR
Intervention: Uncoated surface with standard dose of systemic heparin
Number of subjects: 60
Study 12167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed mediastinal blood
Number of subjects: 60
Study 10460530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 300 mg
Number of subjects: 12
Study 10460530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8591104 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/day orally for 4 to 6 months)
Number of subjects: 247
Study 8591104 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day intranasally for 4 to 6 months)
Number of subjects: 247
Study 2699207 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o. twice daily)
Number of subjects: 18
Study 2699207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2699207 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 18
Study 400192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi‐Siblin
Number of subjects: 29
Study 400192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunelax
Number of subjects: 29
Study 400192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30418322 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 6929
Study 30418322 — intervention group
Group type: COMPARATOR
Intervention: Noninjured individuals (control group)
Number of subjects: 6929
Study 30241275 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-containing regimen (acute phase: olanzapine, ondansetron, dexamethasone; delayed phase: olanzapine, ondansetron)
Number of subjects: 131
Study 30241275 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron/dexamethasone regimen (acute phase: ondansetron, dexamethasone; delayed phase: ondansetron)
Number of subjects: 131
Study 27216835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg/kg ketamine
Number of subjects: 171
Study 27216835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5mg/kg ketamine
Number of subjects: 171
Study 27216835 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg/kg ketamine
Number of subjects: 171
Study 27216835 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ketamine
Number of subjects: 171
Study 24281396 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 180
Study 24281396 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 180
Study 22758599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 112
Study 22758599 — intervention group
Group type: COMPARATOR
Intervention: Adult-led asthma self-management program
Number of subjects: 112
Study 20642544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 87
Study 20642544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 150 mg
Number of subjects: 87
Study 20642544 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 87
Study 20642544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17554160 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling (n = 10)
Number of subjects: 20
Study 17554160 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group (n = 10)
Number of subjects: 20
Study 16351339 — intervention group
Group type: EXPERIMENTAL
Intervention: Even Start family literacy program
Number of subjects: 463
Study 16351339 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 463
Study 11212158 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 246
Study 11212158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg twice daily
Number of subjects: 246
Study 11212158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 9041904 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based weight-bearing exercise program established by a physiotherapist
Number of subjects: 42
Study 9041904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 7524016 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory treatment
Number of subjects: 61
Study 7524016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 61
Study 7524016 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic treatment
Number of subjects: 61
Study 7524016 — intervention group
Group type: COMPARATOR
Intervention: Visual treatment
Number of subjects: 61
Study 3215041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alifedrine 20 mg
Number of subjects: 25
Study 3215041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alifedrine 40 mg
Number of subjects: 25
Study 3215041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alifedrine 40 mg
Number of subjects: 25
Study 3215041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31276430 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported preventive medication use
Number of subjects: 335
Study 31276430 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medication availability at home
Number of subjects: 335
Study 31276430 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous insurance in the prior year
Number of subjects: 335
Study 31276430 — intervention group
Group type: COMPARATOR
Intervention: Medication sharing
Number of subjects: 335
Study 31276430 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled a preventive medication in the past year (subset with pharmacy records)
Number of subjects: 335
Study 31276430 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medication at home (subset with pharmacy records)
Number of subjects: 335
Study 31276430 — intervention group
Group type: COMPARATOR
Intervention: Caregiver report of no preventive medication use in the past 2 weeks
Number of subjects: 335
Study 31276430 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous insurance
Number of subjects: 335
Study 31276430 — intervention group
Group type: COMPARATOR
Intervention: Caregiver education ≥ HS
Number of subjects: 335
Study 31870325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose high-frequency clinical mentorship in EmONC
Number of subjects: 0
Study 31870325 — intervention group
Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 0
Study 28508306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.1% ophthalmic solution
Number of subjects: 152
Study 28508306 — intervention group
Group type: COMPARATOR
Intervention: Timolol Maleate 0.5% ophthalmic solution
Number of subjects: 152
Study 25103271 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 108
Study 23294191 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Number of subjects: 102
Study 23294191 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary intervention)
Number of subjects: 102
Study 21962451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alendronate (125 μg)
Number of subjects: 24
Study 21962451 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (35 mg)
Number of subjects: 24
Study 21962451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and oral alendronate
Number of subjects: 24
Study 21962451 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during the study
Number of subjects: 24
Study 18974581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol for eight weeks
Number of subjects: 27
Study 18974581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16953895 — intervention group
Group type: EXPERIMENTAL
Intervention: SaphLITE Retractor System (n = 100)
Number of subjects: 200
Study 16953895 — intervention group
Group type: COMPARATOR
Intervention: Clearglide Endoscopic Vessel Harvesting System (n = 100)
Number of subjects: 200
Study 12827224 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene plus MFP (60 mg/day raloxifene HCl and 20 mg/day fluoride ions)
Number of subjects: 596
Study 12827224 — intervention group
Group type: COMPARATOR
Intervention: MFP alone (20 mg/day fluoride and placebo)
Number of subjects: 596
Study 12827224 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene plus MFP
Number of subjects: 596
Study 12827224 — intervention group
Group type: COMPARATOR
Intervention: MFP alone
Number of subjects: 596
Study 11096443 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus adjuvant gene therapy during surgery
Number of subjects: 248
Study 11096443 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (surgical resection and radiotherapy)
Number of subjects: 248
Study 9393252 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma probe-directed selective lymph node biopsy
Number of subjects: 63
Study 7963512 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum cuff pressure of 300 mmHg
Number of subjects: 72
Study 7963512 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum cuff pressure of 175 mmHg
Number of subjects: 72
Study 7963512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sphygmomanometric recordings)
Number of subjects: 72
Study 3655512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral subcutaneous sphincterotomy
Number of subjects: 20
Study 3655512 — intervention group
Group type: COMPARATOR
Intervention: Anal dilatation
Number of subjects: 20
Study 3655512 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 control subjects)
Number of subjects: 20
Study 29265838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (interactive online modules)
Number of subjects: 1645
Study 29265838 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 1645
Study 27680325 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (three 60‐min sessions/week of combined aerobic and strength training and pelvic floor exercises)
Number of subjects: 60
Study 27680325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study 27680325 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 60
Study 24411709 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 121
Study 24411709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 21895462 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) intervention (n=27)
Number of subjects: 48
Study 21895462 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 48
Study 20835692 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of +7 cm H₂O
Number of subjects: 80
Study 20835692 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (APL valve opened)
Number of subjects: 80
Study 18183936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum-based immune milk products
Number of subjects: 0
Study 18183936 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunizing cows with pathogens or their antigens
Number of subjects: 0
Study 16361671 — intervention group
Group type: EXPERIMENTAL
Intervention: Achromatic automated perimetry (AAP)
Number of subjects: 51
Study 16361671 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength automated perimetry (SWAP)
Number of subjects: 51
Study 16361671 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency doubling perimetry (FDP)
Number of subjects: 51
Study 12397469 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]acetate PET
Number of subjects: 36
Study 10326536 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM + BCG (1 mg ALM mixed with BCG)
Number of subjects: 3637
Study 10326536 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 3637
Study 10326536 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM + BCG
Number of subjects: 3637
Study 7661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg/d)
Number of subjects: 28
Study 7661605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2718759 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with chewing sticks and toothpaste
Number of subjects: 0
Study 2718759 — intervention group
Group type: COMPARATOR
Intervention: Brushing with chewing sticks only
Number of subjects: 0
Study 766798 — intervention group
Group type: EXPERIMENTAL
Intervention: R & S 218‐M 0.56 mg/70 kg
Number of subjects: 0
Study 766798 — intervention group
Group type: EXPERIMENTAL
Intervention: R & S 218‐M 0.35 mg/70 kg
Number of subjects: 0
Study 766798 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate 10.5 mg/70 kg
Number of subjects: 0
Study 6789777 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied chemotherapeutic drugs (e.g., thiotepa, fluorouracil, betamethasone valerate)
Number of subjects: 30
Study 6789777 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied chemotherapeutic drugs
Number of subjects: 30
Study 31093866 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfluidic chip method
Number of subjects: 428
Study 31093866 — intervention group
Group type: COMPARATOR
Intervention: Density gradient method
Number of subjects: 428
Study 30133419 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-slow breathing (DSB) with slow stretching patterns, performed with eyes closed
Number of subjects: 32
Study 30133419 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow stretching with DSB
Number of subjects: 32
Study 30133419 — intervention group
Group type: EXPERIMENTAL
Intervention: All stretching patterns
Number of subjects: 32
Study 26888692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 114
Study 25299069 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-8000
Number of subjects: 29
Study 25299069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22808006 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin
Number of subjects: 148
Study 19434360 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day omeprazole
Number of subjects: 518
Study 19434360 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day ilaprazole
Number of subjects: 518
Study 19434360 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ilaprazole
Number of subjects: 518
Study 19434360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (ilaprazole and omeprazole)
Number of subjects: 518
Study 18693810 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing methods to detect trends in medication usage
Number of subjects: 0
Study 15013946 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY3-36 (PYY3-36) infusion
Number of subjects: 2
Study 11762428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant discontinuation during week 8 of 12-week group CBT treatment
Number of subjects: 21
Study 11762428 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 21
Study 9826883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath temperature of 37 degrees C (98.6 degrees F) with UVA doses ranging from 0.5 to 5.5 J/cm2
Number of subjects: 0
Study 9826883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower temperatures (below 37 degrees C)
Number of subjects: 0
Study 8121074 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MAG3
Number of subjects: 506
Study 2913139 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (serum levels of 10 to 20 mg/L)
Number of subjects: 10
Study 2913139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg/70 kg)
Number of subjects: 68
Study 1215448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg/70 kg) + Ethanol (0.75 g/kg)
Number of subjects: 68
Study 1215448 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Caffeine
Number of subjects: 68
Study 1215448 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Ethanol
Number of subjects: 68
Study 30585145 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing intervention (community events, educational materials, radio broadcasts)
Number of subjects: 568
Study 30585145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 568
Study 27311739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (VR-based motivational visuomotor feedback training with levodopa)
Number of subjects: 4
Study 27311739 — intervention group
Group type: COMPARATOR
Intervention: Control group (levodopa alone)
Number of subjects: 4
Study 25302624 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks
Number of subjects: 209
Study 25302624 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 209
Study 25302624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 25302624 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg and 400 mg
Number of subjects: 209
Study 25302624 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg, 400 mg, and placebo
Number of subjects: 209
Study 23136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 0
Study 23136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0
Study 23136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 0
Study 21663632 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line HAART
Number of subjects: 188
Study 19372000 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 60
Study 19372000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham procedure)
Number of subjects: 60
Study 16684702 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory steady-state response (ASSR) applied to electric response audiometry (ERA)
Number of subjects: 0
Study 16684702 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSR-ERA
Number of subjects: 0
Study 16684702 — intervention group
Group type: COMPARATOR
Intervention: Conventional pure-tone audiometry
Number of subjects: 0
Study 14724869 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triple antibiotic ointment (TAO)
Number of subjects: 99
Study 14724869 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin ointment
Number of subjects: 99
Study 11593073 — intervention group
Group type: EXPERIMENTAL
Intervention: CX516 added to clozapine
Number of subjects: 19
Study 11593073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9686856 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 40
Study 9686856 — intervention group
Group type: COMPARATOR
Intervention: Argon green laser
Number of subjects: 40
Study 8082050 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day of elemental calcium in the form of calcium pidolate
Number of subjects: 72
Study 8082050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 72
Study 2698444 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention
Number of subjects: 0
Study 2698444 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health strategies
Number of subjects: 0
Study 1269351 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dehydration and reorientation of nursing personnel to delay catheterization
Number of subjects: 500
Study 1269351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction
Number of subjects: 500
Study 30377895 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory biofeedback condition (visual feedback paired to breathing)
Number of subjects: 0
Study 30377895 — intervention group
Group type: COMPARATOR
Intervention: Control feedback placebo condition (visual feedback not paired to breathing)
Number of subjects: 0
Study 30377895 — intervention group
Group type: COMPARATOR
Intervention: Control no-feedback condition (no visual feedback used)
Number of subjects: 0
Study 28799056 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose botulinum toxin type A (BTX-A) injection of 70 to 100 U
Number of subjects: 100
Study 28799056 — intervention group
Group type: COMPARATOR
Intervention: Repeated-dose botulinum toxin type A (BTX-A) injection of 50 to 70 U initially, followed by another of equal volume 2 weeks later
Number of subjects: 100
Study 26268673 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 9
Study 26268673 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital nerve field stimulation (ONFS)
Number of subjects: 9
Study 24500540 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact + Resistance Training (POWIR)
Number of subjects: 51
Study 24500540 — intervention group
Group type: COMPARATOR
Intervention: Exercise Placebo Program (FLEX)
Number of subjects: 51
Study 21164169 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1 μg/kg, intravenous)
Number of subjects: 28
Study 21164169 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 28
Study 19552493 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-fracture use of prescribed calcium plus vitamin D supplements
Number of subjects: 221